Featured Research

from universities, journals, and other organizations

"Sperm And Germ"-Fighting Contraceptive Enters Trials

Date:
January 4, 2002
Source:
Johns Hopkins University
Summary:
Scientists have announced that a new type of contraceptive gel that is also designed to protect against sexually transmitted infections will be the first of its kind to begin clinical efficacy trials at the National Institutes of Health’s Contraceptive Clinical Trials Network.

January 3, 2002 -- Scientists announced today that a new type of contraceptive gel that is also designed to protect against sexually transmitted infections will be the first of its kind to begin clinical efficacy trials at the National Institutes of Health’s Contraceptive Clinical Trials Network.

The gel, known by the brand name BufferGel (tm), was jointly developed by researchers at The Johns Hopkins University and the private firm ReProtect LLC. The new trial will test whether women using BufferGel and a diaphragm can reduce the risk of pregnancy as effectively as women using a conventional spermicidal detergent and a diaphragm.

BufferGel is applied vaginally before sex, like conventional spermicides. Unlike these spermicides, which use detergents to kill sperm, BufferGel contains no soaps. Developers avoided including soap or detergent because they can irritate the vaginal lining after frequent use.

“BufferGel simply reinforces the mild acidity that occurs in the vagina naturally,” says developer Richard Cone, professor of biophysics in Johns Hopkins’ Krieger School of Arts and Sciences. “The normal acidity levels in the vagina can readily kill sperm and many of the germs that cause sexually transmitted infections,” explains Cone, who is also managing director of ReProtect. “That’s why your stomach’s contents are acidic. Most germs just don’t survive long in acidic environments.”

Semen eliminates vaginal acidity for several hours to allow sperm to leave the vagina and enter the uterus. Unfortunately, this also can help make it possible for germs to infect the sexual partner. Cone says BufferGel should block this effect, killing both sperm and germs by rapidly acidifying semen.

While reinforcing the vagina’s natural acidity seemed like a simple enough approach for developing a contraceptive microbicide, several practical considerations made developing a useful compound challenging, according to Cone.

“Not only must the compound kill both sperm and germs, it must do so without hurting the friendly bacteria in a healthy vagina, like the lactobacilli,” he explains. “Also, it mustn’t smell bad or taste bad or stain the sheets. And most importantly, it mustn’t irritate sensitive vaginal tissues.” BufferGel has met those standards both in animal trials and in extensive clinical safety trials, according to Cone.

For the new contraceptive efficacy trial, researchers at 10 sites in the United States are enrolling 1,000 women. Participants must be in a sexually active and monogamous relationship and at low risk for infection by sexually transmitted diseases. They must agree not to use other forms of contraception beyond that supplied by the study, and be willing to risk getting pregnant. Study participants will use a diaphragm with either BufferGel or a conventional spermicide.

“In this trial, we want to achieve the highest possible level of protection,” says Thomas Moench, medical director for ReProtect LLC. “We’re including a diaphragm because it places a discrete physical barrier over the cervix, significantly enhancing the protective actions of contraceptive microbicides.”

Moench, formerly an assistant professor of infectious diseases at the Johns Hopkins Medical Institutions, originally created BufferGel with Cone. Hopkins and ReProtect LLC are developing BufferGel through a cooperative research agreement.

Researchers are also currently planning a larger trial to test BufferGel’s ability to block transmission of HIV and genital herpes. The trial is scheduled to take place through NIH’s HIV Prevention Trials Network next year.

Cone is a part-owner of ReProtect. His financial interests in the research are being managed by Johns Hopkins University in accordance with its conflict-of-interest policies. NIH is funding the trials.

Related web sites:

Richard Cone: http://www.jhu.edu/~biophys/cone/

ReProtect: http://www.ReProtect.com


Story Source:

The above story is based on materials provided by Johns Hopkins University. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins University. ""Sperm And Germ"-Fighting Contraceptive Enters Trials." ScienceDaily. ScienceDaily, 4 January 2002. <www.sciencedaily.com/releases/2002/01/020104074343.htm>.
Johns Hopkins University. (2002, January 4). "Sperm And Germ"-Fighting Contraceptive Enters Trials. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2002/01/020104074343.htm
Johns Hopkins University. ""Sperm And Germ"-Fighting Contraceptive Enters Trials." ScienceDaily. www.sciencedaily.com/releases/2002/01/020104074343.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
US to Track Everyone Coming from Ebola Nations

US to Track Everyone Coming from Ebola Nations

AP (Oct. 22, 2014) Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the US from Ebola-stricken nations will be monitored for symptoms for 21 days. (Oct. 22) Video provided by AP
Powered by NewsLook.com
Doctors Help Paralysed Man Walk Again, Patient in Disbelief

Doctors Help Paralysed Man Walk Again, Patient in Disbelief

AFP (Oct. 22, 2014) Polish doctors describe how they helped a paralysed man walk again, with the patient in disbelief at the return of sensation to his legs. Duration: 1:04 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins